Treatment of Patients Suffering From Nervous Restlessness With PASCOFLAIR®
关键词
抽象
描述
The study was carried out as a prospective, non-interventional study with the intention of subsequent process cost analyses (PCA) and also considers quality of life, drug misuse, dependence, adverse events and therapy satisfaction. Data were collected in collaboration with 22 physicians in Germany.
The study was designed as a one armed non-interventional study. Patients had to suffer from nervous restlessness in order to be eligible for study documentation. Participants agreed to a medical treatment with PASCOFLAIR® of 12 weeks. In this context, documented patients could take PASCOFLAIR® at the first time or could have started within the past three months before the initial visit. Furthermore, documented patients had to be older than 18 years and must be able to read and understand the patient declaration of data protection and the declaration of consent. The patient must not be an alcoholic, must not be drug dependent and have no other types of addiction. Patients who were pregnant or breast-feeding were not eligible for study participation. Furthermore, patients showing hypersensitivity against passionflower extract or against other components of the medication were excluded. The signed declaration of consent of participating patients is available.
The treatment of affected patients may not be documented, if a redemption (written or spoken) of the declaration of consent is existing or the patient takes Benzodiazepines.
日期
最后验证: | 03/31/2017 |
首次提交: | 01/05/2016 |
提交的预估入学人数: | 01/07/2016 |
首次发布: | 01/10/2016 |
上次提交的更新: | 04/03/2017 |
最近更新发布: | 06/18/2017 |
首次提交结果的日期: | 04/20/2016 |
首次提交质量检查结果的日期: | 04/03/2017 |
首次发布结果的日期: | 06/18/2017 |
实际学习开始日期: | 08/31/2014 |
预计主要完成日期: | 05/31/2015 |
预计完成日期: | 05/31/2015 |
状况或疾病
相
资格标准
有资格学习的年龄 | 18 Years 至 18 Years |
有资格学习的性别 | All |
取样方式 | Probability Sample |
接受健康志愿者 | 是 |
标准 | Inclusion Criteria: - patients suffering from nervous restlessness Exclusion Criteria: - Age < 18 years and must be able to read and understand the patient declaration of data protection and the declaration of consent - alcoholics, drug pending, addictive disorder - pregnancy or lactating - patients showing hypersensitivity against passionflower extract or against other components of the medication |
结果
主要结果指标
1. Change of Symptom Inner Restlessness (Pre - Post) [Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)]
次要成果指标
1. Change of Symptom Sleep Disturbance (Pre - Post) [Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)]
2. Change of Symptom Exhaustion (Pre - Post) [Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)]
3. Change of Symptom Fear (Pre - Post) [Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)]
4. Change of Symptom Lack of Concentration (Pre - Post) [Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)]
5. Change of Symptom Transpiration (Pre - Post) [Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline )]
6. Change of Symptom Nausea (Pre - Post) [Change from Baseline (before treatment; week 0) to last visit (end of observation-approx. 12 weeks after baseline)]
7. Change of Symptom Trembling (Pre - Post) [Change from Baseline (before treatment; week 0) to last visit (end of observation - approx. 12 weeks after baseline)]
8. Change of Symptom Palpation (Pre - Post) [Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)]
9. Change of BDEPQ (Benzodiazepine Dependence Questionnaire) [Change from visit 2 (approx. 4 weeks after baseline) to last visit (end of observation- approx. 12 weeks after baseline)]
10. Change of RS-13 (Resilience Questionnaire) (Pre - Post) [Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)]
11. Change in EQ-5D (Health Questionnaire) Scores (Pre - Post) [Change from Baseline (before treatment) to last visit (end of observation- approx. 12 weeks after baseline)]
12. Change of EQ-5D VAS Scores (Pre - Post) [Change from Baseline (before treatment; week 0) to last visit (end of observation- approx. 12 weeks after baseline)]
13. Tolerability Assess Using a 5 Point Scale [Evaluation of Tolerability on visit 3 (appr. 12 weeks after baseline)]